

Summary of Product Characteristics for Pharmaceutical Products

1. Name of the medicinal product:

Entyvio 300 mg powder for concentrate for solution for infusion

2. Qualitative and quantitative composition

Each vial contains 300 mg of Entyvio.

After reconstitution, each ml contains 60 mg of Entyvio.

Entyvio is a humanized IgG₁ monoclonal antibody that binds to the human $\alpha_4\beta_7$ integrin and is produced in Chinese hamster ovary (CHO) cells.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Powder for concentrate for solution for infusion. White to off-white lyophilised cake or powder.

4. Clinical particulars

4.1 Therapeutic indications

Ulcerative Colitis

Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF α) antagonist.

Crohn's Disease

Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF α) antagonist.

Pouchitis

Entyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

4.2 Posology and method of administration

Entyvio treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn's disease (see section 4.4). Patients should be given the package leaflet and the Patient Alert Card.

Posology

Ulcerative Colitis

The recommended dose regimen of Entyvio is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.

Continued therapy for patients with ulcerative colitis should be carefully reconsidered if no evidence of therapeutic benefit is observed by Week 10 (see section 5.1).

Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.

In patients who have responded to treatment with Entyvio, corticosteroids may be reduced and/or discontinued in accordance with standard of care.

Retreatment

If therapy is interrupted and there is a need to restart treatment with Entyvio, dosing at every four weeks may be considered (see section 5.1). The treatment interruption period in clinical trials extended up to one year. Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with Entyvio (see section 4.8).

Crohn's disease

The recommended dose regimen of Entyvio is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.

Patients with Crohn's disease, who have not shown a response may benefit from a dose of Entyvio at Week 10 (see section 4.4). Continue therapy every eight weeks from Week 14 in responding patients. Therapy for patients with Crohn's disease should not be continued if no evidence of therapeutic benefit is observed by Week 14 (see section 5.1).

Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.

In patients who have responded to treatment with Entyvio, corticosteroids may be reduced and/or discontinued in accordance with standard of care.

Retreatment

If therapy is interrupted and there is a need to restart treatment with Entyvio, dosing at every four weeks may be considered (see section 5.1). The treatment interruption period in clinical trials extended up to one year. Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with Entyvio (see section 4.8).

Pouchitis

The recommended dose regimen of intravenous Entyvio is 300 mg administered by intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter.

Treatment with Entyvio should be initiated in parallel with standard of care antibiotic (e.g., four-week of ciprofloxacin) (see section 5.1).

Discontinuation of treatment should be considered if no evidence of therapeutic benefit is observed by 14 weeks of treatment with Entyvio.

Special populations

Paediatric population

The safety and efficacy of Entyvio in children aged 0 to 17 years old have not been established. No data are available.

Elderly patients

No dose adjustment is required in elderly patients. Population pharmacokinetic analyses showed no effect of age (see section 5.2).

Patients with renal or hepatic impairment

Entyvio has not been studied in these patient populations. No dose recommendations can be made.

Pediatric population

The safety and efficacy of Entyvio in children aged 0 to 17 years old have not been established. No data are available.

Method of administration

Entyvio 300 mg powder for concentrate for solution is for intravenous use only. It is to be reconstituted and further diluted prior to intravenous administration, for instructions see section 6.6.

Entyvio 300 mg powder for concentrate for solution is administered as an intravenous infusion over 30 minutes. Patients should be monitored during and after infusion (see section 4.4).

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML) (see section 4.4).

4.4 Special warnings and precautions for use

Entyvio should be administered in a healthcare setting equipped to allow management of acute hypersensitivity reactions including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering Entyvio. All patients should be observed continuously during each infusion. For the first two infusions, they should also be observed for approximately two hours following completion of the infusion for signs and symptoms of acute hypersensitivity reactions. For all subsequent infusions, patients should be observed for approximately one hour following completion of the infusion.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Infusion-related reactions

In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity (see section 4.8).

If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of Entyvio must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines) (see section 4.3).

If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated. Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to Entyvio, in order to minimize their risks (see section 4.8).

Infections

Entyvio is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity (see section 5.1).

Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier (see section 4.8). Entyvio treatment is not to be initiated in patients with active, severe infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with Entyvio. Caution should be exercised when considering the use of Entyvio in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Entyvio is contraindicated in patients with active tuberculosis (see section 4.3). Before starting treatment with Entyvio, patients must be screened for tuberculosis according to the local practice. If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis treatment in accordance with local recommendations, before beginning Entyvio. In patients diagnosed with TB whilst receiving Entyvio therapy, then Entyvio therapy should be discontinued until the TB infection has been resolved.

Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the $\alpha_4\beta_7$ integrin expressed on gut-homing lymphocytes, Entyvio exerts an immunosuppressive effect on the gut. Although no systemic immunosuppressive effect was noted in healthy subjects the effects on systemic immune system function in patients with Inflammatory Bowel Disease patients is not known.

healthcare professionals should monitor patients on Entyvio for any new onset or worsening of neurological signs and symptoms as outlined in physician education materials, and consider neurological referral if they occur. The patient is to be given a Patient Alert Card (see section 4.2). If PML is suspected, treatment with Entyvio must be withheld; if confirmed, treatment must be permanently discontinued.

Malignancies

The risk of malignancy is increased in patients with ulcerative colitis and Crohn's disease. Immunomodulatory medicinal products may increase the risk of malignancy (see section 4.8).

Prior and concurrent use of biological products

No Entyvio clinical trial data are available for patients previously treated with natalizumab or rituximab. Caution should be exercised when considering the use of Entyvio in these patients.

Patients previously exposed to natalizumab should normally wait a minimum of 12 weeks prior to initiating therapy with Entyvio, unless otherwise indicated by the patient's clinical condition.

No clinical trial data for concomitant use of Entyvio with biologic immunosuppressants are available. Therefore, the use of Entyvio in such patients is not recommended.

Live and oral vaccines

In a placebo-controlled study of healthy volunteers, a single 750 mg dose of Entyvio did not lower rates of protective immunity to hepatitis B virus in subjects who were vaccinated intramuscularly with three doses of recombinant hepatitis B surface antigen. Entyvio-exposed subjects had lower seroconversion rates after receiving a killed, oral cholera vaccine. The impact on other oral and nasal vaccines is unknown. It is recommended that all patients be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Entyvio therapy. Patients receiving Entyvio treatment may continue to receive non-live vaccines. There are no data on the secondary transmission of infection by live vaccines in patients receiving Entyvio. Administration of the influenza vaccine should be by injection in line with routine clinical practice. Other live vaccines may be administered concurrently with Entyvio only if the benefits clearly outweigh the risks.

Induction of remission in Crohn's disease

Induction of remission in Crohn's disease may take up to 14 weeks in some patients. The reasons for this are not fully known and are possibly related to the mechanism of action. This should be taken into consideration, particularly in patients with severe active disease at baseline not previously treated with TNF α antagonists. (See also section 5.1.)

Exploratory subgroup analyses from the clinical trials in Crohn's disease suggested that Entyvio administered in patients without concomitant corticosteroid treatment may be less effective for induction of remission in Crohn's disease than in those patients already receiving concomitant corticosteroids (regardless of use of concomitant immunomodulators; see section 5.1).

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Entyvio has been studied in adult ulcerative colitis and Crohn's disease patients with concomitant administration of corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), and aminosalicylates. Population pharmacokinetic analyses suggest that co-administration of such agents did not have a clinically meaningful effect on Entyvio pharmacokinetics. The effect of Entyvio on the pharmacokinetics of commonly co-administered medicinal compounds has not been studied.

In adult patients with pouchitis, Entyvio has been co-administered with antibiotics (see section 5.1). The pharmacokinetics of Entyvio in patients with pouchitis has not been studied (see section 5.2).

Vaccinations

Live vaccines, in particular live oral vaccines, should be used with caution concurrently with Entyvio (see section 4.4).

4.6 Pregnancy and Lactation

Women of childbearing potential

Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and to continue its use for at least 18 weeks after the last treatment with Entyvio.

Pregnancy

There are limited amount of data from the use of Entyvio in pregnant women.

In a small prospective observational study the rate of major birth defects was 7.4% in 99 women with ulcerative colitis or Crohn's disease treated with Entyvio and 5.6% in 76 women with ulcerative colitis or Crohn's disease treated with other biologic agents (adjusted relative risk (RR) 1.07, 95% Confidence Interval (CI): 0.33, 3.52).

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of Entyvio during pregnancy unless the benefits clearly outweigh any potential risk to both the mother and foetus.

Breast-feeding

Entyvio has been detected in human milk. The effect of Entyvio on breast-fed infants and the effects on milk production are unknown. In a milk-only lactation study assessing the concentration of Entyvio in breast milk of lactating women with active ulcerative colitis or Crohn's disease receiving Entyvio, the concentration of Entyvio in human breast milk was approximately 0.4% to 2.2% of the maternal serum concentration obtained from historical studies of Entyvio. The estimated average daily dose of Entyvio ingested by the infant was 0.02 mg/kg/day, which is approximately 21% of the body weight-adjusted average maternal daily dose. The use of Entyvio in lactating women should take into account the benefit of therapy to the mother and potential risks to the infant.

Fertility

There are no data on the effects of Entyvio on human fertility. Effects on male and female fertility have not been formally evaluated in animal studies (see section 5.3).

4.7 Effects on ability to drive and use machines

Entyvio may have a minor influence on the ability to drive or operate machines, as dizziness has been reported in a small number of patients.

4.8 Undesirable effects

Summary of safety profile

The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory tract infection, bronchitis, influenza and sinusitis), headache, nausea, pyrexia, fatigue, cough, arthralgia. Infusion related reactions (with symptoms such as dyspnoea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate) have also been reported in patients treated with Entyvio.

Tabulated list of adverse reactions

The following listing of adverse reactions is based on clinical trial and post marketing experience and is displayed by system organ class. Within the system organ classes, adverse reactions are listed under headings of the following frequency categories: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), very rare ($< 1/10,000$) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 1. Adverse reactions		
System organ class	Frequency	Adverse reaction(s)
Infections and infestations	Very common	Nasopharyngitis
	Common	Pneumonia, Clostridium difficile infection, Bronchitis, Gastroenteritis, Upper respiratory tract infection, Influenza, Sinusitis, Pharyngitis, Herpes zoster
	Uncommon	Respiratory tract infection, Vulvovaginal candidiasis, Oral candidiasis
Immune system disorders	Very rare	Anaphylactic reaction,

		Anaphylactic shock
Nervous system disorders	Very common	Headache
	Common	Paraesthesia
Eye disorders	Uncommon	Blurred vision
Vascular disorders	Common	Hypertension
Respiratory, thoracic and mediastinal disorders	Common	Oropharyngeal pain, Nasal congestion, Cough
	Not known	Interstitial lung disease
Gastrointestinal disorders	Common	Anal Abscess, Anal fissure, Nausea, Dyspepsia, Constipation, Abdominal distension, Flatulence, Haemorrhoids, Rectal haemorrhage*
Hepatobiliary disorders	Common	Liver enzyme increased
	Very rare	Hepatitis
Skin and subcutaneous tissue disorders	Common	Rash, Pruritus, Eczema, Erythema, Night sweats, Acne
	Uncommon	Folliculitis
Musculoskeletal and connective tissue disorders	Very common	Arthralgia
	Common	Muscle spasms, Back pain, Muscular weakness, Fatigue, Pain in the extremity
General disorders and administration site conditions	Common	Pyrexia, Infusion related reaction (asthenia* and chest discomfort*), Infusion site reaction (including: Infusion site pain and Infusion site irritation)
	Uncommon	Chills, Feeling cold
*Reported in the EARNEST pouchitis study		

Description of selected adverse reactions

Infusion-related reactions

In GEMINI I and II controlled studies, 4% of Entyvio-treated patients and 3% of placebo-treated patients experienced an adverse event defined by the investigator as infusion-related reaction (IRR) (see section 4.4). No individual Preferred Term reported as an IRR occurred at a rate above 1%. The majority of IRRs were mild or moderate in intensity and <1% resulted in discontinuation of study treatment. Observed IRRs generally resolved with no or minimal intervention following the infusion. Most infusion related reactions occurred within the first 2 hours. Of those patients who had infusion related reactions, those dosed with Entyvio had more infusion related reactions within the first two hours as compared to placebo patients with infusion related reactions. Most infusion related reactions were not serious and occurred during the infusion or within the first hour after infusion is completed.

One serious adverse event of IRR was reported in a Crohn's disease patient during the second infusion (symptoms reported were dyspnoea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate) and was successfully managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. In patients who received Entyvio at Weeks 0 and 2 followed by placebo, no increase in the rate of IRR was seen upon retreatment with Entyvio after loss of response.

In EARNEST controlled study (pouchitis) with intravenous Entyvio, hypersensitivity reactions, including IRRs, were reported in 3 out of 51 subjects (5.9%) in the Entyvio group and 2 out of 51 subjects (3.9%) in the placebo group. The individual Preferred Terms included mouth ulceration, swelling, oedema peripheral, chest discomfort, asthenia, acute kidney injury, obstructive airway disorder and flushing. All events were reported as mild to moderate in intensity, none were considered serious and none resulted in study discontinuation.

Infections

In GEMINI I and II controlled studies, the rate of infections was 0.85 per patient-year in the Entyvio-treated patients and 0.70 per patient-year in the placebo-treated patients. The infections consisted primarily of nasopharyngitis, upper respiratory tract infection, sinusitis, and urinary tract infections. Most patients continued on Entyvio after the infection resolved.

In GEMINI I and II controlled studies, the rate of serious infections was 0.07 per patient year in Entyvio-treated patients and 0.06 per patient year in placebo-treated patients. Over time, there was no significant increase in the rate of serious infections.

In the EARNEST controlled study (pouchitis) with intravenous Entyvio, only 1 out of 51 subjects (2.0%) in the Entyvio group experienced a serious infection of gastroenteritis. The subject was hospitalized for observation, recovered from the event and completed the study.

In controlled and open-label studies in adults with Entyvio, serious infections have been reported, which include tuberculosis, sepsis (some fatal), salmonella sepsis, listeria meningitis, and cytomegaloviral colitis.

In clinical studies with intravenous Entyvio (ulcerative colitis and Crohn's disease), the rate of infections in Entyvio-treated patients with BMI of 30 kg/m² and above was higher than for those with BMI less than 30 kg/m².

In clinical studies with intravenous Entyvio (ulcerative colitis and Crohn's disease), a slightly higher incidence of serious infections was reported in Entyvio-treated patients who had prior exposure to TNF α antagonist therapy compared to patients who were naïve to previous TNF α antagonist therapy.

Immunogenicity

In GEMINI I and II controlled studies, Entyvio showed an immunogenicity rate of 4% (56 of 1,434 patients who received continuous treatment with Entyvio were anti-Entyvio antibody-positive at any time during treatment). Nine out of 56 patients were persistently positive (anti-Entyvio antibody-positive at two or more study visits) and 33 patients developed neutralizing anti-Entyvio antibodies.

The frequency of anti-Entyvio antibody detected in patients 16 weeks after the last dose of Entyvio (approximately five half-lives after the last dose) was approximately 10% in GEMINI I and II.

In GEMINI I and II controlled studies, 5% (3 of 61) of the patients who had an adverse event assessed by the investigator as an IRR were persistently anti-Entyvio antibody-positive.

Overall, there was no apparent correlation of anti-Entyvio antibody development to clinical response or adverse events. However, the number of patients that developed anti-Entyvio antibodies was too limited to make a definitive assessment.

Malignancy

Overall, results from the clinical program to date do not suggest an increased risk for malignancy with Entyvio treatment; however, the number of malignancies was small and long-term exposure was limited. Long-term safety evaluations are ongoing.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via pharmacy and poisons board, Pharmacovigilance Electronic Reporting System (PvERS) 23

<https://pv.pharmacyboardkenya.org>

4.9 Overdose

Doses up to 10 mg/kg (approximately 2.5 times the recommended dose) have been administered in clinical trials. No dose-limiting toxicity was seen in clinical trials.

5. Pharmacological properties

Pharmacotherapeutic group: immunosuppressants, selective immunosuppressants, ATC code: L04AA33.

5.1 Pharmacodynamic properties

Entyvio is a gut-selective immunosuppressive biologic. It is a humanized monoclonal antibody that binds specifically to the $\alpha_4\beta_7$ integrin, which is preferentially expressed on gut homing T helper lymphocytes. By binding to $\alpha_4\beta_7$ on certain lymphocytes, Entyvio inhibits adhesion of these cells to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), but not to vascular cell adhesion molecule-1 (VCAM-1). MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to tissues within the gastrointestinal tract. Entyvio does not bind to, nor inhibit function of, the $\alpha_4\beta_1$ and $\alpha_E\beta_7$ integrins.

The $\alpha_4\beta_7$ integrin is expressed on a discrete subset of memory T helper lymphocytes which preferentially migrate into the gastrointestinal (GI) tract and cause inflammation that is characteristic of ulcerative colitis and Crohn's disease, both of which are chronic inflammatory immunologically mediated conditions of the GI tract. Entyvio reduces gastrointestinal inflammation in UC patients. Inhibiting the interaction of $\alpha_4\beta_7$ with MAdCAM-1 with Entyvio prevents transmigration of gut-homing memory T helper lymphocytes across the vascular endothelium into parenchymal tissue in nonhuman primates and induced a reversible 3-fold elevation of these cells in peripheral blood. The murine precursor of Entyvio alleviated gastrointestinal inflammation in colitic cotton-top tamarins, a model of ulcerative colitis.

In healthy subjects, ulcerative colitis patients, or Crohn's disease patients, Entyvio does not elevate neutrophils, basophils, eosinophils, B-helper and

cytotoxic T lymphocytes, total memory T helper lymphocytes, monocytes or natural killer cells, in the peripheral blood with no leukocytosis observed.

Entyvio did not affect immune surveillance and inflammation of the central nervous system in Experimental Autoimmune Encephalomyelitis in non-human primates, a model of multiple sclerosis. Entyvio did not affect immune responses to antigenic challenge in the dermis and muscle (see section 4.4). In contrast, Entyvio inhibited an immune response to a gastrointestinal antigenic challenge in healthy human volunteers (see section 4.4).

Immunogenicity

Antibodies to Entyvio may develop during Entyvio treatment most of which are neutralising. The formation of anti-Entyvio antibodies is associated with increased clearance of Entyvio and lower rates of clinical remission.

Infusion related reactions after Entyvio infusion are reported in subjects with anti-Entyvio antibodies.

Pharmacodynamic effects

In clinical trials with intravenous Entyvio at doses ranging from 0.2 to 10 mg/kg, > 95% saturation of $\alpha_4\beta_7$ receptors on subsets of circulating lymphocytes involved in gut immune surveillance was observed in patients.

Change in the ratio of CD4⁺ /CD8⁺ in cerebrospinal fluid pre- and post-Entyvio administration in healthy human volunteers. These data are consistent with investigations in nonhuman primates which did not detect effects on immune surveillance of the CNS.

Clinical efficacy and safety

Ulcerative Colitis

The efficacy and safety of Entyvio for the treatment of adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopic sub score ≥ 2) was demonstrated in a randomised, double-blind, placebo-controlled study evaluating efficacy endpoints at Week 6 and Week 52 (GEMINI I). Enrolled patients had failed at least one conventional therapy, including corticosteroids, immunomodulators, and/or the TNF α antagonist infliximab (including primary non-responders). Concomitant stable doses of oral aminosalicylates, corticosteroids and/or immunomodulators were permitted.

For the evaluation of the Week 6 endpoints, 374 patients were randomised in a double-blind fashion (3:2) to receive Entyvio 300 mg or placebo at Week 0 and Week 2. Primary endpoint was the proportion of patients with clinical response (defined as reduction in complete Mayo score of ≥ 3 points and $\geq 30\%$ from baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point) at Week 6. Table 2 shows the results from the primary and secondary endpoints evaluated.

Table 2. Week 6 Efficacy Results of GEMINI I

Endpoint	Placebo N=149	Entyvio N=225
Clinical response	26%	47%*
Clinical remission [§]	5%	17% [†]
Mucosal healing [¶]	25%	41% [‡]

*p<0.0001

[†]p \leq 0.001

[‡]p<0.05

[§]Clinical remission: Complete Mayo score of ≤ 2 points and no individual subscore > 1 point

[¶]Mucosal healing: Mayo endoscopic subscore of ≤ 1 point

The beneficial effect of Entyvio on clinical response, remission and mucosal healing was observed both in patients with no prior TNF α antagonist exposure as well as in those who had failed prior TNF α antagonist therapy.

In GEMINI I, two cohorts of patients received Entyvio at Week 0 and Week 2: cohort 1 patients were randomised to receive either Entyvio 300 mg or placebo in a double-blind fashion, and cohort 2 patients were treated with open-label Entyvio 300 mg. To evaluate efficacy at Week 52, 373 patients from cohort 1 and 2 who were treated with Entyvio and had achieved clinical

response at Week 6 were randomised in a double-blind fashion (1:1:1) to one of the following regimens beginning at Week 6: Entyvio 300 mg every eight weeks, Entyvio 300 mg every four weeks, or placebo every four weeks. Beginning at Week 6, patients who had achieved clinical response and were receiving corticosteroids were required to begin a corticosteroid-tapering regimen. Primary endpoint was the proportion of patients in clinical remission at Week 52. Table 3 shows the results from the primary and secondary endpoints evaluated.

Table 3. Week 52 Efficacy Results of GEMINI I

Endpoint	Placebo N = 126*	Entyvio Every 8 Weeks N = 122	Entyvio Every 4 Weeks N = 125
Clinical remission	16%	42% [†]	45% [†]
Durable clinical response [¶]	24%	57% [†]	52% [†]
Mucosal healing	20%	52% [†]	56% [†]
Durable clinical remission [#]	9%	20% [§]	24% [‡]
Corticosteroid-free clinical remission [*]	14%	31% [§]	45% [†]

*The placebo group includes those subjects who received Entyvio at Week 0 and Week 2, and were randomised to receive placebo from Week 6 through Week 52.

[†]p<0.0001

[‡]p<0.001

[§]p<0.05

[¶]Durable clinical response: Clinical response at Weeks 6 and 52

[#]Durable clinical remission: Clinical remission at Weeks 6 and 52

^{*}Corticosteroid-free clinical remission: Patients using oral corticosteroids at baseline who had discontinued corticosteroids beginning at Week 6 and were in clinical remission at Week 52. Patient numbers were n=72 for placebo, n=70 for Entyvio every eight weeks, and n=73 for Entyvio every four weeks

Exploratory analyses provide additional data on key subpopulations studied. Approximately one-third of patients had failed prior TNF antagonist therapy. Among these patients, 37% receiving Entyvio

every eight weeks, 35% receiving Entyvio every four weeks, and 5% receiving placebo achieved clinical remission at Week 52. Improvements in durable clinical response (47%, 43%, 16%), mucosal healing (42%, 48%, 8%), durable clinical remission (21%, 13%, 3%) and corticosteroid-free clinical remission (23%, 32%, 4%) were seen in the prior TNF α antagonist failure population treated with Entyvio every eight weeks, Entyvio every four weeks and placebo, respectively.

Patients who failed to demonstrate response at Week 6 remained in the study and received Entyvio every four weeks. Clinical response using partial Mayo scores was achieved at Week 10 and Week 14 by greater proportions of Entyvio patients (32% and 39%, respectively) compared with placebo patients (15% and 21%, respectively).

Patients who lost response to Entyvio when treated every eight weeks were allowed to enter an open-label extension study and receive Entyvio every four weeks. In these patients, clinical remission was achieved in 25% of patients at Week 28 and Week 52.

Patients who achieved a clinical response after receiving Entyvio at Week 0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open-label extension study and receive Entyvio every four weeks. In these patients, clinical remission was achieved in 45% of patients by 28 weeks and 36% of patients by 52 weeks.

In this open-label extension study, the benefits of Entyvio treatment as assessed by partial Mayo score, clinical remission, and clinical response were shown for up to 196 weeks.

Health-related quality of life (HRQOL) was assessed by Inflammatory Bowel Disease Questionnaire (IBDQ), a disease specific instrument, and SF-36 and EQ-5D, which are general measures.

Exploratory analysis show clinically meaningful improvements were observed for Entyvio groups, and the improvements were significantly greater as compared with the placebo group at Week 6 and Week 52 on EQ-5D and EQ-5D VAS scores, all subscales of IBDQ (bowel symptoms, systemic function, emotional function and social function), and all subscales of SF-36 including the Physical Component Summary (PCS) and Mental Component Summary (MCS).

Crohn's Disease

The efficacy and safety of Entyvio for the treatment of adult patients with moderately to severely active Crohn's Disease (Crohn's Disease Activity Index [CDAI] score of 220 to 450) were evaluated in two

studies (GEMINI II and III). Enrolled patients have failed at least one conventional therapy, including corticosteroids, immunomodulators, and/or TNF α antagonists (including primary non-responders). Concomitant stable doses of oral corticosteroids, immunomodulators, and antibiotics were permitted.

The GEMINI II Study was a randomised, double-blind, placebo-controlled study evaluating efficacy endpoints at Week 6 and Week 52. Patients (n=368) were randomised in a double-blind fashion (3:2) to receive two doses of Entyvio 300 mg or placebo at Week 0 and Week 2. The two primary endpoints were the proportion of patients in clinical remission (defined as CDAI score ≤ 150 points) at Week 6 and the proportion of patients with enhanced clinical response (defined as a ≥ 100 -point decrease in CDAI score from baseline) at Week 6 (see Table 4).

GEMINI II contained two cohorts of patients that received Entyvio at Weeks 0 and 2: Cohort 1 patients were randomised to receive either Entyvio 300 mg or placebo in a double-blind fashion, and Cohort 2 patients were treated with open-label Entyvio 300 mg. To evaluate efficacy at Week 52, 461 patients from Cohorts 1 and 2, who were treated with Entyvio and had achieved clinical response (defined as a ≥ 70 -point decrease in CDAI score from baseline) at Week 6, were randomised in a double-blind fashion (1:1:1) to one of the following regimens beginning at Week 6: Entyvio 300 mg every eight weeks, Entyvio 300 mg every four weeks, or placebo every four weeks. Patients showing clinical response at Week 6 were required to begin corticosteroid tapering. Primary endpoint was the proportion of patients in clinical remission at Week 52 (see Table 5).

The GEMINI III Study was a second randomised, double-blind, placebo-controlled study that evaluated efficacy at Week 6 and Week 10 in the subgroup of patients defined as having failed at least one conventional therapy and failed TNF α antagonist therapy (including primary non-responders) as well as the overall population, which also included patients who failed at least one conventional therapy and were naïve to TNF α antagonist therapy. Patients (n=416), which included approximately 75% TNF α antagonist failures patients, were randomised in a double-blind fashion (1:1) to receive either Entyvio 300 mg or placebo at Weeks 0, 2, and 6. The primary endpoint was the proportion of patients in clinical remission at Week 6 in the TNF α antagonist failure subpopulation. As noted in Table 4, although the primary endpoint was not met, exploratory analyses show that clinically meaningful results were observed.

Table 4. Efficacy Results for GEMINI II and III Studies at Week 6 and Week 10

Study Endpoint	Placebo	Entyvio
GEMINI II Study		
Clinical remission, Week 6		
Overall	7% (n = 148)	15%* (n = 220)
TNFα Antagonist(s) Failure	4% (n = 70)	11% (n = 105)
TNFα Antagonist(s) Naïve	9% (n = 76)	17% (n = 109)
Enhanced clinical response, Week 6		
Overall	26% (n = 148)	31%† (n = 220)
TNFα Antagonist(s) Failure	23% (n = 70)	24% (n = 105)
TNFα Antagonist(s) Naïve	30% (n = 76)	42% (n = 109)
Serum CRP change from baseline to Week 6, median (mcg/mL)		
Overall‡	-0.5 (n = 147)	-0.9 (n = 220)
GEMINI III Study		
Clinical remission, Week 6		
Overall‡	12% (n = 207)	19% (n = 209)
TNFα Antagonist(s) Failure¶	12% (n = 157)	15%§ (n = 158)
TNFα Antagonist(s) Naïve	12% (n = 50)	31% (n = 51)
Clinical remission, Week 10		
Overall	13% (n = 207)	29% (n = 209)
TNFα Antagonist(s) Failure¶,‡	12% (n = 157)	27% (n = 158)
TNFα Antagonist(s) Naïve	16% (n = 50)	35% (n = 51)
Sustained clinical remission#,¶		
Overall	8% (n = 207)	15% (n = 209)
TNFα Antagonist(s) Failure¶,‡	8% (n = 157)	12% (n = 158)
TNFα Antagonist(s) Naïve	8% (n = 50)	26% (n = 51)
Enhanced clinical response, Week 6		
Overall^	23% (n = 207)	39% (n = 209)
TNFα Antagonist(s) Failure‡	22% (n = 157)	39% (n = 158)

TNFα Antagonist(s) Naïve [^]	24% (n = 50)	39% (n = 51)
--	--------------	--------------

*p<0.05
†not statistically significant
‡secondary endpoint to be viewed as exploratory by pre-specified statistical testing procedure
§not statistically significant, the other endpoints were therefore not tested statistically
¶n=157 for placebo and n=158 for Entyvio
#Sustained clinical remission: clinical remission at Weeks 6 and 10
^Exploratory Endpoint

Table 5. Efficacy Results for GEMINI II at Week 52

	Placebo N=153*	Entyvio Every 8 Weeks N=154	Entyvio Every 4 Weeks N=154
Clinical remission	22%	39% [†]	36% [‡]
Enhanced clinical response	30%	44% [‡]	45% [‡]
Corticosteroid-free clinical remission [§]	16%	32% [‡]	29% [‡]
Durable clinical remission [¶]	14%	21%	16%

*The placebo group includes those subjects who received Entyvio at Week 0 and Week 2, and were randomised to receive placebo from Week 6 through Week 52.

[†]p<0.001

[‡]p<0.05

[§]Corticosteroid-free clinical remission: Patients using oral corticosteroids at baseline who had discontinued corticosteroids beginning at Week 6 and were in clinical remission at Week 52. Patient numbers were n=82 for placebo, n=82 for Entyvio every eight weeks, and n=80 for Entyvio every four weeks

[¶]Durable clinical remission: Clinical remission at ≥80% of study visits including final visit (Week 52)

Exploratory analyses examined the effects of concomitant corticosteroids and immunomodulators on induction of remission with Entyvio. Combination treatment, most notably with concomitant corticosteroids, appeared to be more effective in inducing remission in Crohn's disease than Entyvio alone or with concomitant immunomodulators, which showed a smaller difference from placebo in the rate of remission. Clinical remission rate in GEMINI II at Week 6 was 10% (difference from placebo 2%, 95% CI: -6, 10) when administered without corticosteroids compared to 20% (difference from placebo 14%, 95% CI: -1, 29) when administered with concomitant corticosteroids. In GEMINI III at Week 6 and 10 the respective clinical remission rates were 18% (difference from

placebo 3%, 95% CI: -7, 13) and 22% (difference from placebo 8%, 95% CI: -3, 19) when administered without corticosteroids compared to 20% (difference from placebo 11%, 95% CI: 2, 20) and 35% (difference from placebo 23%, 95% CI: 12, 33) respectively when administered with concomitant corticosteroids. These effects were seen whether or not immunomodulators were also concomitantly administered.

Exploratory analyses provide additional data on key subpopulations studied. In GEMINI II, approximately half of patients had previously failed TNF α antagonist therapy. Among these patients, 28% receiving Entyvio every eight weeks, 27% receiving Entyvio every four weeks, and 13% receiving placebo achieved clinical remission at Week 52. Enhanced clinical response was achieved in 29%, 38%, 21%, respectively, and corticosteroid-free clinical remission was achieved in 24%, 16%, 0%, respectively.

Patients who failed to demonstrate response at Week 6 in GEMINI II were retained in the study and received Entyvio every four weeks. Enhanced clinical response was observed at Week 10 and Week 14 for greater proportions of Entyvio patients 16% and 22%, respectively, compared with placebo patients 7% and 12%, respectively. There was no clinically meaningful difference in clinical remission between treatment groups at these time points. Analyses of Week 52 clinical remission in patients who were non-responders at Week 6 but achieved response at Week 10 or Week 14 indicate that non-responder CD patients may benefit from a dose of Entyvio at Week 10.

Patients who lost response to Entyvio when treated every eight weeks in GEMINI II were allowed to enter an open-label extension study and received Entyvio every four weeks. In these patients, clinical remission was achieved in 23% of patients at Week 28 and 32% of patients at Week 52.

Patients who achieved a clinical response after receiving Entyvio at Week 0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open-label extension study and receive Entyvio every four weeks. In these patients, clinical remission was achieved in 46% of patients by 28 weeks and 41% of patients by 52 weeks.

In this open-label extension study, clinical remission and clinical response were observed in patients for up to 124 weeks.

Exploratory analysis showed clinically meaningful improvements were observed for the Entyvio every four weeks and every eight weeks groups in GEMINI II and the improvements were significantly greater as compared with the placebo group from baseline to Week

52 on EQ-5D and EQ-5D VAS scores, total IBDQ score, and IBDQ subscales of bowel symptoms and systemic function.

Pouchitis

The efficacy and safety of intravenous Entyvio for the treatment of adult patients with chronic pouchitis were demonstrated in a randomised, double-blind, placebo-controlled study evaluating efficacy at week 14 and week 34 (EARNEST). Enrolled patients had undergone proctocolectomy and ileal pouch anal anastomosis (IPAA) for ulcerative colitis at least one year prior to randomisation and had developed active chronic pouchitis (defined as antibiotic-dependent (recurrent) or antibiotic-refractory), with a baseline modified Pouchitis Disease Activity Index (mPDAI) score ≥ 5 and endoscopic subscore ≥ 2 . All patients received concomitant antibiotic treatment with ciprofloxacin 500 mg twice daily from the start of treatment through week 4. Patients received additional courses of antibiotics during the study as needed, including for pouchitis flares.

Patients (n=102) were randomised (1:1) to receive either intravenous Entyvio 300 mg or intravenous placebo at 0, 2 and 6 weeks, and every 8 weeks thereafter, until week 30. The primary endpoint was clinical remission (defined as an mPDAI score < 5 and a reduction in total mPDAI score of ≥ 2 points from baseline) at week 14. Table 6 shows the results from the primary and secondary endpoints at week 14 and Table 7 shows the results from secondary endpoints at week 34.

Table 6. Efficacy results for EARNEST at week 14

Endpoint	Placebo n = 51	Entyvio IV n = 51	Difference Entyvio-Placebo (95% CI) [percentage points]
Clinical remission*	9.8%	31.4% [†]	21.6 (4.9, 37.5)
PDAI remission [‡]	9.8%	35.3%	25.5 (8.0, 41.4)
Clinical response [§]	33.3%	62.7%	29.4 (8.0, 47.6)
*Clinical remission is defined as mPDAI score < 5 and a reduction in total mPDAI score of ≥ 2 points from baseline [†] p < 0.05 [‡] PDAI remission is defined as PDAI score < 7 and a reduction in PDAI score of ≥ 3 points from baseline [§] Clinical response is defined as reduction of mPDAI score of ≥ 2 points from baseline			

Table 7. Efficacy results for EARNEST at week 34

Endpoint	Placebo n = 51	Entyvio IV n = 51	Difference Entyvio-Placebo (95% CI)
----------	-------------------	----------------------	---

			[percentage points]
Clinical remission*	17.6%	35.3%	17.6 (0.3, 35.1)
PDAI remission‡	17.6%	37.3%	19.6 (1.9, 37.0)
Clinical response§	29.4%	51.0%	21.6 (1.9, 39.8)
<p>*Clinical remission is defined as mPDAI score < 5 and reduction in total mPDAI score of ≥ 2 points from baseline</p> <p>‡ PDAI remission is defined as PDAI score < 7 and a reduction in PDAI score of ≥ 3 points from baseline</p> <p>§Clinical response is defined as reduction of mPDAI score of ≥ 2 points from baseline</p>			

Approximately two-thirds of patients had received prior (for UC or pouchitis) TNF α antagonist therapy (33 in Entyvio and 31 in placebo treatment groups). Among these patients, 33.3% in the Entyvio group achieved clinical remission at W14 compared with 9.7% in the placebo group.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Entyvio in one or more subsets of the paediatric population in ulcerative colitis and Crohn's disease (see section 4.2).

5.2 Pharmacokinetic properties

The single and multiple dose pharmacokinetics of Entyvio have been studied in healthy subjects and in patients with moderate to severely active ulcerative colitis or Crohn's disease.

In patients administered 300 mg Entyvio as a 30 minute intravenous infusion on Weeks 0 and 2, mean serum trough concentrations at Week 6 were 27.9 mcg/ml (SD ± 15.51) in ulcerative colitis and 26.8 mcg/ml (SD ± 17.45) in Crohn's disease. Starting at Week 6, patients received 300 mg Entyvio every eight or four weeks. In patients with ulcerative colitis, mean steady-state serum trough concentrations were 11.2 mcg/ml (SD ± 7.24) and 38.3 mcg/ml (SD ± 24.43), respectively. In patients with Crohn's disease mean steady-state serum trough concentrations were 13.0 mcg/ml (SD ± 9.08) and 34.8 mcg/ml (SD ± 22.55),

respectively.

Distribution

Population pharmacokinetic analyses indicate that the distribution volume of Entyvio is approximately 5 litres. The plasma protein binding of Entyvio has not been evaluated. Entyvio is a therapeutic monoclonal antibody and is not expected to bind to plasma proteins.

Entyvio does not pass the blood brain barrier after intravenous administration. Entyvio 450 mg administered intravenously was not detected in the cerebrospinal fluid of healthy subjects.

Elimination

Population pharmacokinetic analyses indicate that Entyvio has a total body clearance of approximately 0.157 L/day and a serum half-life of 25 days. The exact elimination route of Entyvio is not known. Population pharmacokinetic analyses suggest that while low albumin, higher body weight, prior treatment with anti-TNF drugs and presence of anti-Entyvio antibody may increase Entyvio clearance, the magnitude of their effects is not considered to be clinically relevant.

Linearity

Entyvio exhibited linear pharmacokinetics at serum concentrations greater than 1 mcg/ml.

Special populations

Age does not impact the Entyvio clearance in ulcerative colitis and Crohn's disease patients based on the population pharmacokinetic analyses. No formal studies have been conducted to examine the effects of either renal or hepatic impairment on the pharmacokinetics of Entyvio.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, as well as reproductive and development toxicology studies.

Long-term animal studies with Entyvio to assess its carcinogenic potential have not been conducted because pharmacologically responsive models to monoclonal antibodies do not exist. In a pharmacologically responsive species (cynomolgus monkeys), there was no evidence of cellular hyperplasia or systemic immunomodulation that could potentially be associated with oncogenesis in 13- and 26-week toxicology studies. Furthermore, no effects were found of Entyvio on the proliferative rate or

cytotoxicity of a human tumour cell line expressing the $\alpha_4\beta_7$ integrin in vitro.

No specific fertility studies in animals have been performed with Entyvio. No definitive conclusion can be drawn on the male reproductive organs in cynomolgus monkey repeated dose toxicity study, but given the lack of binding of Entyvio to male reproductive tissue in monkey and human, and the intact male fertility observed in β_7 integrin-knockout mice, it is not expected that Entyvio will affect male fertility.

Administration of Entyvio to pregnant cynomolgus monkeys during most of gestation resulted in no evidence of effects on teratogenicity, prenatal or postnatal development in infants up to 6 months of age. Low levels (<300 mcg/L) of Entyvio were detected on post-partum Day 28 in the milk of 3 of 11 cynomolgus monkeys treated 100 mg/kg of Entyvio dosed every 2 weeks and not in any animals that received 10 mg/kg. It is not known whether Entyvio is excreted in human milk.

6. Pharmaceutical Particulars

6.1 List of Excipients

L-histidine
L-histidine
monohydrochloride
L-arginine
hydrochloride
sucrose
polysorbate 80

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf-Life

3 years

In-use stability of the reconstituted solution in the vial has been demonstrated for 8 hours at 2°C-8°C.

In-use stability of the diluted solution in sodium chloride 9 mg/mL (0.9%) solution for injection in infusion bag has been demonstrated for 12 hours at 20°C-25°C or 24 hours at 2°C-8°C.

The combined in-use stability of Entyvio in the vial and infusion bag with sodium chloride 9 mg/mL (0.9%) solution for injection is a total of 12 hours at 20°C-25°C or 24 hours at 2°C-8°C. A 24 hour period may include up to 8 hours at 2°C-8°C for reconstituted solution in the vial and up to 12 hours at 20°C-25°C for diluted solution in the infusion bag but the infusion bag must be stored in the refrigerator (2°C-8°C) for the rest of the 24 hour period.

Do not freeze the reconstituted solution in the vial or the diluted solution in the infusion bag.

	Storage condition	
	Refrigerator (2°C-8°C)	20°C-25°C
Reconstituted solution in the vial	8 hours	Do not hold ¹
Diluted solution in sodium chloride 9 mg/mL (0.9%) solution for injection	24 hours ^{2,3}	12 hours ²

¹ Up to 30 minutes are allowed for reconstitution

² This time assumes the reconstituted solution is immediately diluted in the sodium chloride 9 mg/mL (0.9%) solution for injection and held in the infusion bag only. Any time that the reconstituted solution was held in the vial should be subtracted from the time the solution may be held in the infusion bag.

³ This period may include up to 12 hours at 20 °C-25 °C.

6.4 Special Precautions for storage

Store in a refrigerator (2°C-8°C). Keep the vial in the outer carton in order to protect from light. For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.

6.5 Nature and Content of container

Entyvio 300 mg powder for concentrate for solution for infusion in Type 1 glass vial (20 ml) fitted with rubber stopper and aluminium crimp protected by a plastic cap.

Each pack contains 1 vial.

6.6 Special precautions for disposal and other handling

Instructions for reconstitution and infusion

Entyvio should be at room temperature (20°C-25°C) when reconstituted.

1. Use aseptic technique when preparing Entyvio solution for intravenous infusion.
 2. Remove flip-off cap from the vial and wipe with alcohol swab. Reconstitute Entyvio with 4.8 mL of sterile water for injections at room temperature (20 °C-25 °C), using a syringe with a 21-25 gauge needle.
 3. Insert the needle into the vial through the centre of the stopper and direct the stream of liquid to the wall of the vial to avoid excessive foaming.
 4. Gently swirl the vial for at least 15 seconds. Do not vigorously shake or invert.
 5. Let the vial sit for up to 20 minutes at room temperature (20 °C-25 °C), to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution.
 6. Inspect the reconstituted solution visually for particulate matter and discoloration prior to dilution. Solution should be clear or opalescent, colorless to light yellow and free of visible particulates. Reconstituted solution with uncharacteristic colour or containing particulates must not be administered.
 7. Once dissolved, gently invert vial 3 times.
 8. Immediately withdraw 5 mL (300 mg) of reconstituted Entyvio using a syringe with a 21–25-gauge needle.
 9. Add the 5 mL (300 mg) of reconstituted Entyvio to 250 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection, and gently mix the infusion bag (5 mL of sodium chloride 9 mg/mL (0.9%) solution for injection does not have to be withdrawn from the infusion bag prior to adding Entyvio). Do not add other medicinal products to the prepared infusion solution or intravenous infusion set. Administer the infusion solution over 30 minutes (see section 4.2).
- Once reconstituted, the infusion solution should be used as soon as possible.
- Do not store any unused portion of the reconstituted solution or infusion solution for reuse.

Each vial is for single use only.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing Authorization Holder

Takeda Pharma A/S

Dybendal Alle 10

2630 Taastrup

Denmark

8. Marketing Authorization Number

CTD7332

9. Date of first authorization/renewal of the authorization

Date of first authorisation: 03/02/2023

10. Date of revision of the text

08MAY 2025